Careful though, not to look at it in a vacuum. He may be down $750K with CYDY, but maybe he was/will be using that to offset gains in other places. We have no idea. I agree, he is probably not deaf, but I don't see the point in not releasing the info if it's good, verifiable, and actually would move the needle, thus putting CYDY in a far more favorable position of strength in several areas. This has NOTHING to do with the FDA, unless they have to massage the data to make it look more positive than it really is, which they know is not a smart move at this point. Good data is good data, and the FDA cannot tell you not to release good data.